Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The incidence of colorectal cancer liver metastasis is high and the prognosis is poor.
Improving the treatment effect of colorectal cancer liver metastasis is the key to improving
the prognosis of colorectal cancer patients. Rigofenib is one of the standard third-line
treatments for advanced colorectal cancer, but has limited efficacy. Immune checkpoint
inhibitors (PD-L1 monoclonal antibody, PD-1 monoclonal antibody) have achieved good results
in the treatment of various malignant tumors. In a mouse transplant tumor model of colorectal
cancer, regorafenib combined with PD-1 monoclonal antibody treatment significantly improved
the antitumor activity, but the efficacy rate in clinical studies was not very high,
especially for liver metastases. Radiofrequency ablation (RFA) is one of the common methods
for the treatment of liver metastases. RFA may improve the immune microenvironment and the
efficacy of immunotherapy,and the purpose of this trial is to explore the efficacy and safety
of rigofenib and terepliumab combined with RFA in patients with refractory colorectal cancer
liver metastasis.